Saw Palmetto
Saw Palmetto (Serenoa repens)
A botanical 5-alpha reductase inhibitor whose only high-quality trials (in BPH) showed no benefit over placebo; the positive AGA data are small and low-quality.
How Saw Palmetto works — and how well we know it
Contains free fatty acids and phytosterols that weakly inhibit 5-alpha reductase — qualitatively the same mechanism as finasteride and dutasteride but several orders of magnitude weaker in laboratory assays. Likely also has some peripheral androgen receptor binding activity.
oral, topical
320 mg/day standardized lipidosterolic extract (oral). Topical preparations also studied at varying concentrations.
Marketed as a dietary supplement. Approved as an OTC therapy for benign prostatic hyperplasia in several European countries; not FDA-approved for AGA.
Patients who want a botanical 5-AR inhibitor and accept a much smaller expected benefit, or who can't tolerate finasteride/dutasteride.
Evidence distribution across 3 claims
Why the grade is D. Hair evidence is limited to one tiny combined-ingredient placebo RCT (Prager 2002, n=26, no hair counts) and one open-label finasteride comparison (Rossi 2012). The shared 5-alpha reductase mechanism has been tested rigorously for BPH and failed: three high-quality RCTs (Bent STEP 2006 NEJM; Barry CAMUS 2011 JAMA, at triple dose) and a Cochrane review (Tacklind 2012, n=582) all found no benefit over placebo — undercutting confidence in the small, low-quality AGA signals.
Every claim, traced back to its source
We took every major claim made about Saw Palmetto and matched it to the specific experimental model behind it. Click a claim to see the model, the finding, and our assessment of how much weight it deserves.
3 claims · evidence-by-evidence breakdown
1In VitroWeight: LowSaw palmetto extract weakly inhibits 5-alpha reductase in vitroReal 5-AR inhibition mechanism, but vastly weaker than finasteride at any achievable dose.
Cell-free enzyme assays and prostate-tissue assays demonstrating 5-alpha reductase inhibition by saw palmetto's free fatty acids and sterols.
Saw palmetto extract inhibits both type I and type II 5-AR, but at concentrations several orders of magnitude higher than required for finasteride.
The mechanism is real but qualitatively weak. In vitro potency doesn't translate cleanly to in vivo effect because of bioavailability and tissue concentration limits — which likely explains the modest clinical effect size.
- Iehlé C et al. (1995). J Steroid Biochem Mol Biol PMID 7626456
2RCTWeight: ModeratePrager 2002 double-blind RCT (saw palmetto + beta-sitosterol) showed improvement vs. placeboPositive signal but tiny n=26, combined-ingredient design, and only global assessment — supportive but far from conclusive.
Double-blind, placebo-controlled RCT, n=26 (10 active / 7 placebo / 9 had complications), 21 weeks. Men aged 23-64 with mild-to-moderate AGA. Active arm received saw palmetto extract 200 mg + beta-sitosterol 50 mg, twice daily.
60% of treated subjects rated as improved at study endpoint vs. 11% of placebo, based on investigator global photographic assessment.
First placebo-controlled trial of saw palmetto for AGA — and the foundation for most subsequent marketing claims. Very small sample, combined-ingredient design (can't isolate the saw palmetto effect from beta-sitosterol), and only investigator global assessment (no hair counts). Effect direction is positive but the trial is far too small for definitive conclusions.
- Prager N et al. (2002). J Altern Complement Med PMID 11975504
3Open-LabelWeight: ModerateRossi 2012 compared saw palmetto vs. finasteride head-to-headDirect head-to-head: saw palmetto helps about 38% of men vs. 68% with finasteride. Real but much weaker.
Open-label comparison study, n=100 (50 saw palmetto 320 mg/day vs. 50 finasteride 1 mg/day), 24 months. Men with mild-to-moderate AGA.
38% of saw palmetto patients showed improvement vs. 68% of finasteride patients at 24 months. Finasteride showed greater improvement particularly at the vertex.
The single best head-to-head data we have — and it confirms that saw palmetto does something, but roughly half as much as finasteride. Open-label design is a limitation, but the difference between arms is large and consistent with the in vitro potency gap.
- Rossi A et al. (2012). Int J Immunopathol Pharmacol PMID 23298508
What's still missing from the science
- A large (>200), independently-funded, placebo-controlled RCT of saw palmetto monotherapy with phototrichogram endpoints.
- Long-term safety and efficacy data beyond 2 years.
- Dose-response data — is 320 mg the optimal dose, or could higher doses approach finasteride?
- Topical saw palmetto RCT vs. topical minoxidil.
Our verdict on Saw Palmetto
Not in our formulary yet
We don't carry this ingredient. We only formulate around actives where the evidence — and the safety profile — is strong enough to recommend with confidence. As the data matures, we may revisit.
Related treatments
How does Saw Palmetto stack up against its closest peers?
A genuine cause of reversible hair shedding in iron-deficient patients — but useless and potentially harmful if your iron stores are normal.
Read the breakdown →One small Malaysian RCT showed a hair-count increase. Never replicated. Used by Nutrafol to justify its tocotrienol content.
Read the breakdown →Correlated with AGA in observational studies. No RCT yet shows that supplementation reverses or slows hair loss.
Read the breakdown →